Background Lefamulin, a pleuromutilin antibiotic, is active against pathogens commonly
causing community-acquired bacterial pneumonia (CABP). The Lefamulin Evaluation …

Lefamulin, the first semisynthetic pleuromutilin antibacterial for intravenous and oral
treatment of community-acquired bacterial pneumonia (CABP), and comparators were …

Lefamulin is a novel oral and intravenous (IV) pleuromutilin developed as a twice-daily
treatment for community-acquired bacterial pneumonia (CABP). It is a semi-synthetic …

The emergence and spread of antimicrobial resistance have led to a global public health
emergency requiring development of new antimicrobial classes. Lefamulin (formally BC …

Introduction: Community-acquired pneumonia is the most common infection leading to
hospitalization and death in all age groups, especially in elderly populations. Increasing …

Background Lefamulin is a pleuromutilin antibiotic under evaluation for the treatment of
bacterial infections, including respiratory tract infections. Currently, there are no high-quality …

Importance New antibacterials are needed to treat community-acquired bacterial pneumonia
(CABP) because of growing antibacterial resistance and safety concerns with standard care …

Objectives To present results of preclinical studies that supported further development of
lefamulin for treating patients with community-acquired bacterial pneumonia (CABP) …

This study investigated the potential of the novel systemic pleuromutilin antibiotic BC-3781
to treat patients with an acute bacterial skin and skin structure infection (ABSSSI) caused by …

Background BC-3781 is an investigational semi-synthetic pleuromutilin antibiotic, which
recently finished a clinical Phase 2 trial in acute bacterial skin and skin structure infections …